Status:
UNKNOWN
Blood Loss After Early TXA in Hip Fractures.
Lead Sponsor:
Community Memorial Health System
Conditions:
Hip Fractures
Eligibility:
All Genders
18+ years
Phase:
EARLY_PHASE1
Brief Summary
Our present study aims to initiate TXA administration immediately upon diagnosis of hip fracture in the Emergency Department. This will be a single blind randomized controlled trial comparing early ad...
Detailed Description
Consent will be obtained for study enrollment from the patient or legal decision maker. The patient will then be randomized and stratified based on the fracture type, fixation method anticipated, and ...
Eligibility Criteria
Inclusion
- Femoral neck, intertrochanteric, subtrochanteric femur fracture
- Age \>18
- Undergoing surgical stabilization or arthroplasty by any method as determined by attending surgeon
Exclusion
- Age \<18
- Concomitant fracture
- Preoperative anemia needing blood transfusion before surgery
- Severe comorbidity (active cancer, severe pulmonary disease, ESRD)
- Allergy for tranexamic acid
- History of acute thromboembolic event (Deep Vein Thrombosis, Pulmonary Embolism, Stroke, TIA) in the previous 12 months
- Myocardial infarction in the previous 12 months
- Renal function impairment (creatinine clearance \<30 mL/min), or kidney transplant
- History of hypercoagulability (Factor V Leiden, Protein C/S deficiency)
Key Trial Info
Start Date :
July 6 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2023
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT04488367
Start Date
July 6 2020
End Date
July 1 2023
Last Update
July 19 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Community Memorial Hospital
Ventura, California, United States, 93003